On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
By deploying a "tag and sort" fix using E3 ligases, scientists successfully cleared the protein buildup and restored T-cell ...
CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...
T cells are crucial components of our immune system, serving as critical protectors against infection and disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results